Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells - PubMed (original) (raw)
Review
. 2003 Jun;10(11):983-90.
doi: 10.1038/sj.gt.3302038.
Affiliations
- PMID: 12756419
- DOI: 10.1038/sj.gt.3302038
Review
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells
H Wakimoto et al. Gene Ther. 2003 Jun.
Abstract
Several clinical trials have or are being performed testing the safety and efficacy of different strains of oncolytic viruses (OV) for malignant cancers. OVs represent either naturally occurring or genetically engineered strains of viruses that exhibit relatively selective replication in tumor cells. Several types of OV have been derived from herpes simplex virus 1 (HSV1). Tumor oncolysis depends on the processes of initial OV infection of tumor, followed by subsequent propagation of OV within the tumor itself. The role of the immune responses in these processes has not been extensively studied. On the contrary, effects of the immune response on the processes of wild-type HSV1 infection and propagation in the central nervous system have been studied and described in detail. The first line of defense against a wild-type HSV1 infection in both naive and immunized individuals is provided by innate humoral (complement, cytokines, chemokines) and cellular (macrophages, neutrophils, NK cells, gammadelta T cells, and interferon-producing cells) responses. These orchestrate the lysis of virions and virus-infected cells as well as provide a link to effective adaptive immunity. The role of innate defenses in curtailing the oncolytic effect of genetically engineered HSV has only recently been studied, but several of the same host responses appear to be operative in limiting anticancer effects by the replicating virus. The importance of this knowledge lies in finding avenues to modulate such initial innate responses, in order to allow for increased oncolysis of tumors while minimizing host toxicity.
Similar articles
- Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis.
Wakimoto H, Fulci G, Tyminski E, Chiocca EA. Wakimoto H, et al. Gene Ther. 2004 Jan;11(2):214-23. doi: 10.1038/sj.gt.3302143. Gene Ther. 2004. PMID: 14712306 Free PMC article. - Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy.
Bowers WJ, Olschowka JA, Federoff HJ. Bowers WJ, et al. Gene Ther. 2003 Jun;10(11):941-5. doi: 10.1038/sj.gt.3302047. Gene Ther. 2003. PMID: 12756414 Review. - Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG, Horvath JC. Sinkovics JG, et al. Arch Immunol Ther Exp (Warsz). 2008 Dec;56 Suppl 1:3s-59s. doi: 10.1007/s00005-008-0047-9. Epub 2008 Dec 23. Arch Immunol Ther Exp (Warsz). 2008. PMID: 19104757 Review. - Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
Kambara H, Saeki Y, Chiocca EA. Kambara H, et al. Cancer Res. 2005 Dec 15;65(24):11255-8. doi: 10.1158/0008-5472.CAN-05-2278. Cancer Res. 2005. PMID: 16357128 - Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.
Friedman A, Tian JP, Fulci G, Chiocca EA, Wang J. Friedman A, et al. Cancer Res. 2006 Feb 15;66(4):2314-9. doi: 10.1158/0008-5472.CAN-05-2661. Cancer Res. 2006. PMID: 16489036
Cited by
- Synergistic effects of herpes oncolytic virus and cyclophosphamide for recurrent malignant glioma: a narrative review.
Iqbal J, Hafeez MH, Amin A, Moradi I, Chhabra A, Iqbal A, Patel T, Shafique MA, Nadeem A, Jamil U. Iqbal J, et al. Ann Med Surg (Lond). 2024 Jul 17;86(9):5354-5360. doi: 10.1097/MS9.0000000000002384. eCollection 2024 Sep. Ann Med Surg (Lond). 2024. PMID: 39239066 Free PMC article. Review. - Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies.
Gao X, Liu J, Sun R, Zhang J, Cao X, Zhang Y, Zhao M. Gao X, et al. Ann Hematol. 2024 Aug;103(8):2569-2589. doi: 10.1007/s00277-023-05488-9. Epub 2023 Oct 18. Ann Hematol. 2024. PMID: 37853078 Review. - Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment.
Yang L, Ning Q, Tang SS. Yang L, et al. J Immunol Res. 2022 Mar 18;2022:8052212. doi: 10.1155/2022/8052212. eCollection 2022. J Immunol Res. 2022. PMID: 35340585 Free PMC article. Review. - Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.
Blitz SE, Kappel AD, Gessler FA, Klinger NV, Arnaout O, Lu Y, Peruzzi PP, Smith TR, Chiocca EA, Friedman GK, Bernstock JD. Blitz SE, et al. Int J Mol Sci. 2022 Feb 4;23(3):1808. doi: 10.3390/ijms23031808. Int J Mol Sci. 2022. PMID: 35163730 Free PMC article. Review. - Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.
Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, Markert JM. Miller KE, et al. Clin Cancer Res. 2022 Feb 1;28(3):498-506. doi: 10.1158/1078-0432.CCR-21-2636. Clin Cancer Res. 2022. PMID: 35105718 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical